EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improving cervical screening risk stratification through extended human papillomavirus genotyping and age-specific data

Aarno Leino iD, Eero Numminen, Veronika Fonagy, Minna Paloniemi, Tapio Seiskari, Ivana Kholová, Saara Kares, Karolina Louvanto iD

European Journal of Public Health · 04.08.2026 · 36 (5)

DOI: 10.1093/eurpub/ckag139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Public Health, online erschienen am 17.08.2026. Verfasst von Aarno Leino und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Early Detection of Cancer, Human Papillomavirus Viruses. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sigrid Juselius Foundation, Finnish Cancer Foundation, Tampere University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-risk human papillomavirus (HR-HPV) screening effectively reduces cervical cancer incidence, but limited specificity leads to excessive colposcopy referrals. Extended HR-HPV genotyping improves triage by accounting for genotype-specific oncogenic risks, offering a more precise framework for patient management than traditional pooled testing. This study analysed real-world screening data from a Finnish cohort of 2368 HR-HPV-positive women (Tampere region, 2017–2019) with up to 6.5 years of follow-up. Extended genotyping was performed using the Seegene Anyplex™II HPV28 Detection assay. Genotype-specific prevalence and cumulative incidence of histology-confirmed High-grade Squamous Intraepithelial Lesions or worse (HSIL+) were assessed and stratified by reflex cytology. Among 3099 detected HR-HPV genotypes, HPV16 was most prevalent (14.3%) and carried the highest HSIL+ risk (35.7%), followed by HPV33 (24.6%) and HPV18 (20.8%). A clear risk hierarchy emerged: the lowest-risk group (HPV59/39/68/51/56/66) had an HSIL+ incidence below 4.2%. Notably, HPV16-positive women with NILM/ASC-US cytology faced a 23.9% HSIL+ risk, exceeding the 21.1% risk seen in the lowest-risk genotype group even when accompanied by LSIL+ cytology. For those with both NILM/ASC-US and the lowest-risk genotypes, HSIL+ incidence was only 3.4%. A distinct hierarchy of oncogenic risk exists within this population-based cohort. Incorporating genotype-specific data into national screening algorithms is strongly supported. This allows for immediate colposcopy for high-risk groups (e.g. HPV16 with mild cytology) while justifying extended follow-up for lower-risk types, optimizing clinical resources and reducing unnecessary procedures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus InfectionsEarly Detection of CancerHuman Papillomavirus VirusesPapillomaviridaeHumansFemaleFinlandAdultGenotypeMiddle AgedRisk AssessmentIncidenceMass ScreeningAge FactorsAged

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Department of Microbiology, Fimlab Laboratories, Tampere, Finland.
  • Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Department of Pathology, Fimlab Laboratories, Tampere, Finland.
  • Department of Pathology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland.

ORCID-Profile: Aarno Leino, Karolina Louvanto

Förderung

  • Sigrid Juselius Foundation
  • Finnish Cancer Foundation
  • Tampere University Hospital
  • Wellbeing services county of Pirkanmaa
  • Research Council of Finland

Zitieren

APA

Leino, A., Numminen, E., Fonagy, V., Paloniemi, M., Seiskari, T., Kholová, I., Kares, S., & Louvanto, K. (2026). Improving cervical screening risk stratification through extended human papillomavirus genotyping and age-specific data. European Journal of Public Health, 36(5). https://doi.org/10.1093/eurpub/ckag139

Vancouver

Leino A, Numminen E, Fonagy V, Paloniemi M, Seiskari T, Kholová I, et al. Improving cervical screening risk stratification through extended human papillomavirus genotyping and age-specific data. European Journal of Public Health. 2026;36(5). doi:10.1093/eurpub/ckag139

BibTeX
@article{Leino2026,
  author = {Leino, Aarno and Numminen, Eero and Fonagy, Veronika and Paloniemi, Minna and Seiskari, Tapio and Kholová, Ivana and Kares, Saara and Louvanto, Karolina},
  title = {Improving cervical screening risk stratification through extended human papillomavirus genotyping and age-specific data},
  journal = {European Journal of Public Health},
  year = {2026},
  volume = {36},
  number = {5},
  doi = {10.1093/eurpub/ckag139}
}
Kostenlos starten →